This consultation closed on 1 April 2024
The APVMA is considering an application for approval of the new active constituent, tetracosactide and the registration of the product, CosACTHen 0.25mg/mL Solution for Injection for Dogs, for the evaluation of adrenocortical function in dogs.
We invite comments from 5 March 2024 to 1 April 2024 on whether approval of the active constituent and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- chemistry and manufacture
- occupational health and safety
- public health
- environmental safety
- efficacy and target animal safety.
For more information see page 19, APVMA Gazette No. 5 March 2024.
Please send your written submission by email or post to:
Case Management and Administration Unit
Australian Pesticides and Veterinary Medicines Authority
GPO Box 3262
Sydney NSW 2001
Phone: +61 2 6770 2300
Email: casemanagement@apvma.gov.au